Aceragen, Inc.
ACGN Healthcare Biotechnology
Aceragen, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $4.9 million. Operating cash flow growth for five consecutive years.
Follow ACGN
Aceragen, Inc. (ACGN) EV/Sales
As of 20 March 2023, Aceragen, Inc. (ACGN) trades at a EV/Sales of 4.1×. Over the past ten years it has ranged from −13.8× (January 2019) to 7,300× (December 2015); the current reading is higher than 17% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | 6.6× | 19.14% |
| FY2019 | 5.5× | 42.81% |
| FY2018 | 3.8× | (98.52%) |
| FY2017 | 261× | 5,005.88% |
| FY2016 | 5.1× | (99.57%) |
| FY2015 | 1,189× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2022 | 6.6× | (47.36%) |
| Sep 2022 | 12.4× | 4.43% |
| Jun 2019 | 11.9× | 209.53% |
| Dec 2018 | 3.8× | (98.17%) |
| 15 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TCRX TScan Therapeutics, Inc. compare | −5.3× |
| ATYR aTyr Pharma, Inc. compare | −3.4× |
| NEUP Neuphoria Therapeutics Inc. compare | −0.3× |
| JSPR Jasper Therapeutics, Inc. compare | n/m |
| RADX Radiopharm Theranostics Limited - Sponsored ADR compare | n/m |
| ANEB Anebulo Pharmaceuticals, Inc. compare | n/m |
| PBM Psyence Biomedical Ltd. compare | n/m |
| DYAI Dyadic International Inc. compare | 4.0× |
| ACGN Aceragen, Inc. | 4.1× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)